We are live on ! Find out more
RNAM

Avidity Biosciences
RNAM

Delisted

RNAM was delisted on the 26th of February, 2026.

Back to rankings

144 hedge funds and large institutions have $701M invested in Avidity Biosciences in 2023 Q4 according to their latest regulatory filings, with 25 funds opening new positions, 53 increasing their positions, 47 reducing their positions, and 23 closing their positions.

New
Increased
Maintained
Reduced
Closed

119% more call options, than puts

Call options by funds: $756K | Put options by funds: $345K

34% more capital invested

Capital invested by funds: $522M → $701M (+$179M)

13% more repeat investments, than reductions

Existing positions increased: 53 | Existing positions reduced: 47

1% more funds holding

Funds holding: 142 → 144 (+2)

9% more first-time investments, than exits

New positions opened: 25 | Existing positions closed: 23

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

5.84% less ownership

Funds ownership: 110.3% → 104.46% (-5.8%)

Holders
144
Holders Change
+2
Holders Change %
+1.41%
% of All Funds
2.1%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
25
Increased
53
Reduced
47
Closed
23
Calls
$756K
Puts
$345K
Net Calls
+$411K
Net Calls Change
-$176K

Top Buyers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
+$12.2M
2
LGM
Logos Global Management
California
+$5.18M
3
BlackRock
BlackRock
New York
+$4.75M
4
Deutsche Bank
Deutsche Bank
Germany
+$4.2M
5
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$2.01M

Top Sellers

Rank Fund Capital Flow
1
RCM
RA Capital Management
Massachusetts
-$26.5M
2
CAM
Cormorant Asset Management
Massachusetts
-$11.2M
3
Balyasny Asset Management
Balyasny Asset Management
Illinois
-$5.37M
4
State Street
State Street
Massachusetts
-$4.83M
5
Fidelity Investments
Fidelity Investments
Massachusetts
-$4.75M
Name Holding Trade Value Shares
Change 		Change in
Stake
Two Sigma Advisers
26
Two Sigma Advisers
New York
$4.56M -$236K -35,300 -7%
Citadel Advisors
27
Citadel Advisors
Florida
$4.47M +$1.76M +263,314 +114%
N
28
Nuveen
North Carolina
$4.44M +$1.87M +279,718 +133%
AllianceBernstein
29
AllianceBernstein
Tennessee
$3.39M -$1.02M -152,939 -29%
Goldman Sachs
30
Goldman Sachs
New York
$3.2M -$817K -122,265 -26%
Millennium Management
31
Millennium Management
New York
$3.08M -$2.67M -399,880 -54%
Wellington Management Group
32
Wellington Management Group
Massachusetts
$2.64M +$288K +43,147 +17%
CS
33
Candriam SCA
Luxembourg
$2.63M +$802K +120,000 +71%
Rafferty Asset Management
34
Rafferty Asset Management
New York
$2.44M -$795K -118,923 -31%
TD Asset Management
35
TD Asset Management
Ontario, Canada
$2.42M – – –
Bank of America
36
Bank of America
North Carolina
$2.36M -$666K -99,606 -28%
Bank of New York Mellon
37
Bank of New York Mellon
New York
$2.34M +$44.2K +6,616 +3%
Renaissance Technologies
38
Renaissance Technologies
New York
$2.05M +$775K +115,900 +105%
Barclays
39
Barclays
United Kingdom
$1.79M +$58.8K +8,794 +5%
Marshall Wace
40
Marshall Wace
United Kingdom
$1.79M +$1.32M +197,716 New
UBS Group
41
UBS Group
Switzerland
$1.76M +$524K +78,387 +68%
Wells Fargo
42
Wells Fargo
California
$1.73M -$69.5K -10,399 -5%
PBM
43
Propel Bio Management
California
$1.62M +$1.19M +178,500 New
Mirae Asset Global Investments
44
Mirae Asset Global Investments
South Korea
$1.5M +$833K +124,633 +301%
Manulife (Manufacturers Life Insurance)
45
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$1.44M +$109K +16,343 +11%
MOACM
46
Mutual of America Capital Management
New York
$1.35M +$102K +15,245 +11%
GCP
47
GSA Capital Partners
United Kingdom
$1.3M -$1.31M -195,477 -58%
AWA
48
Aaron Wealth Advisors
Illinois
$1.21M +$5.54K +828 +0.6%
SSA
49
Schonfeld Strategic Advisors
New York
$1.18M +$18.8K +2,817 +2%
RJA
50
Raymond James & Associates
Florida
$1.18M +$245K +36,666 +39%
1
2
3 4 5

RNAM Hedge Fund Activity: Q4 2023 in Review

144 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Avidity Biosciences (RNAM) for Q4 2023, worth a combined $701M — up 34% from $522M a quarter earlier.

Buyers outnumbered sellers: 25 funds opened new RNAM positions and 23 closed out — a net gain of 2 holders — while 53 added to existing stakes and 47 trimmed.

The largest buyer was Morgan Stanley, adding an estimated $12.2M. The largest seller was RA Capital Management, cutting an estimated $26.5M.

  • 144 institutional investors held Avidity Biosciences (RNAM) as of Q4 2023, up from 142 in Q3 2023.
  • Funds reported $701M of Avidity Biosciences stock for Q4 2023, up 34% quarter-over-quarter.
  • 25 funds opened new Avidity Biosciences positions in Q4 2023 and 23 closed out, a net change of +2 holders.
  • The largest Avidity Biosciences buyer in Q4 2023 was Morgan Stanley, an estimated $12.2M added.
  • The largest Avidity Biosciences seller in Q4 2023 was RA Capital Management, an estimated $26.5M sold.

Based on aggregated 13F filings for Q4 2023.